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is the most in clinical treatment, and it is also a hot and difficult issue of current research.
Many previous studies confirmed that epithelial mesenchymal transition (EMT) is one of the main mechanisms that cause the dispersion of malignant tumors. 3 EMT triggers a variety of biological changes in normal mammary epithelial cells, which eventually obtains the characteristics of mesenchymal cells. This effect enhances the metastasis capacity, invasiveness and resistance of cancer cells, thereby preventing apoptosis and promoting the production of extracellular matrix components. 4 The occurrence of EMT is related to a variety of molecular mechanisms and signaling pathways. 5 Its main function is the reduction of intercellular adhesion and E-cadherin, mesenchymal vimentin, and N-cadherin expression. Moreover, many transcriptional factors, including snail and ZEB, have crucial roles in EMT-induced processes. 6 The ZEB family (ZEB1 and ZEB2) is closely related to the EMT-related markers of malignant tumors. 7 However, the regulatory role of lncRNA-ZEB2-AS1 in ZEB2 expression in breast cancer remains unreported.
LncRNA is a kind of regulatory RNA that has a transcriptional length of more than 200 nucleotides and has no protein coding ability. 8 LncRNA plays a vital role in malignant tumor development, especially in apoptosis, proliferation, and invasion. [9] [10] [11] Abnormal lncRNA expression is observed in malignant tumors, such as gastric cancer, hepatocellular carcinoma (HCC), and glioma. [12] [13] [14] Moreover, lncRNA is a competitive endogenous RNA (ceRNAs) that regulates miRNA. 15, 16 Despite the significant role lncRNA in malignant tumor development, its regulatory functions and molecular mechanisms remain poorly understood.
In this study, we found that abnormal lncRNA-ZEB2-AS1 expression is associated with patient survival and prognosis and controls ZEB2 expression. In the MDA231 cells, LncRNA-ZEB2-AS1 promoted the proliferation and metastasis of tumor cells and triggered EMT via the PI3K/Akt/GSK3β/Zeb2 signaling pathway and F-actin polymerization.
| MATERIAL AND ME THODS

| Clinical specimens
We obtained breast cancer specimens (BC) and adjacent no tumor 
| Cell culture
MCF-10A, T47D, MDA-MB-435 (MDA435), MCF-7, and MDA-MB-231(MDA231) were acquired from ATCC (USA). The cells were cultured in minimum essential medium with 10% fetal bovine serum (FBS) at 37℃ under 5% CO 2 atmosphere.
| Plasmid construction and cell transfection
MDA231 cells (2 × 10 5 ) were planted in six-well plates and left overnight. We used Lipofectamine 2000 to transfect the MDA231 cells in accordance with the manufacturer protocol Lnc-ZEB2-AS1-RNAi, and si-NC plasmids were constructed by GeneChem company (shanghai, China) Sequences were provided in Table S1 .
Stable transfected cells were maintained with 300 μg/mL G418 for 14 days.
| Wound healing assay
Approximately 2 × 10 5 breast cancer cells were planted onto six-well plates and then left overnight. Wounds were created with a 10 μL pipette tip. Complete medium including 1% FBS was added to the plates with or without EGF. The entire setup was photographed after 36 hours.
| Cell proliferation assays
For the cell counting kit 8 (CCK-8; Solarbio, Beijing) assays, approximately 2 × 10 3 cells were seeded in a 96-well plate. The proliferation capacities of the cells cultured for 24, 48, 72, 96 , and 120 hours were tested by the CCK-8 assays. The cell growth curves were plotted by using the absorbance value at each time point. 
| Transwell assay
| Western blot
Protein expression was examined as described previously. 17 The following antibodies were employed: ZEB2 (Santa Cruz, 
| Quantitative real-time PCR
We performed Quantitative real-time PCR (QRT-PCR) to define the relative level of lncRNA-ZEB2-AS1. GAPDH levels were used for normalization. We used TRIzol to extract RNA from fresh breast cancer specimens and cells. Then, cDNA was synthesized with the total RNA by using an M-MLV reverse transcriptase kit (Promega, USA). Relative mRNA expression was normalized through the 2 − ΔΔCT method. QRT-PCR was carried out using an Applied Biosystems 7500. 
| Cellular F-actin measurement
| Immunofluorescence
The MDA231 cells were fixed with 4% paraformaldehyde for 25 min.
The cells were permeabilized with 0.1% Triton X-100 and blocked with goat serum for 45 min at 37°C. The primary antibodies of relation were incubated at 4°C overnight. FITC, Cy3-labeled goat antirabbit IgG secondary antibodies, and DAPI were used.
| Animal studies
The Server Combined Immune-deficiency (SCID) mice were pro- ) were injected into the oxter of each female SCID mouse (n = 10). When the xenografts became evident, tumor volume was measured. After 7 weeks, metastasis in the lung tissues was examined by HE staining.
| Statistical analysis
Data were analyzed by SPSS v16.0. All values were expressed as mean ± SD. The results were analyzed with T test or ANOVA. Χ The data revealed that lncRNA-ZEB2-AS1 expression was markedly
The differentially expressed of lncRNA-ZEB2-AS1 in breast cancer specimens and cells. A, Expression of lncRNA-ZEB2-AS1 in 98 pairs of BC and ANT specimens. B, Differentially expressed lncRNA-ZEB2-AS1 in breast cancer specimens with and without lymph node metastasis. C, LncRNA-ZEB2-AS1 detected in MCF-7, T47D, MDA231, MDA435 and MCF-10A cells. D, LncRNA-ZEB2-AS1 localization in the nucleus and cytoplasm was tested. E, Kaplan-Meier method analysis (log-rank test) was carried out for the verification of relationship between abnormal lncRNA-ZEB2-AS1 expression and poor prognosis (*, P < 0.05).
up-regulated in breast cancer cells compared with MCF-10A cells.
The expression levels of highly invasive MDA231 cells and MDA435
were higher lncRNA-ZEB2-AS1, and those of invasive cells T47D and MCF-7 were lower than lncRNA-ZEB2-AS1 ( Figure 1C ). LncRNA is considered to have different biological functions in different locations of the cells. Meanwhile, we first detected the distribution of lncRNA-ZEB2-AS1 in the MDA231 cells. LncRNA-ZEB2-AS1 was mainly located in the nucleus was minimally expressed in the cytoplasm ( Figure 1D ). Additionally, breast cancer patients with high lncRNA-ZEB2-AS1 levels have shorter survival rates than those with low levels ( Figure 1E) . The relationship between lncRNA-ZEB2-AS1 expression level and the clinicopathologic features of breast cancer patients was evaluated. LncRNA-ZEB2-AS1 expression is highly associated with tumor differentiation, lymph node metastasis, and distant metastasis in breast cancer but not associated with age or tumor size ( Table 1 ). The results indicated that lncRNA-ZEB2-AS1 plays an oncogenic role and is associated with clinicopathologic features and decreased survival of breast cancer patients.
| Knockdown of lncRNA-ZEB2-AS1 suppressed the proliferation and invasion of MDA231 cells
The TA B L E 1 Correlation between lncRNA-ZEB2-AS1 expression and clinicopathological features of breast cancer patients the MDA231/si-ZEB2-AS1 group had significantly reduced pulmonary metastatic foci ( Figure 3D ).
| Knockdown of lncRNA-ZEB2-AS1 led to the down-regulation of ZEB2 expression through PI3K/Akt/GSK3β/Zeb2 signaling pathway and inhibited EMT
The upstream antisense transcription may affect corresponding gene expression. 19 LncRNA-ZEB2-AS1 is an antisense lncRNA. We Figure 5A,B) . Meanwhile, LIMK and cofilin are two vital proteins related to the regulation of F-actin polymerization. 20 We detected the phosphorylation status of LIMK and cofilin, to confirm whether lncRNA-ZEB2-AS1 inhibits EGF-induced rearrangement of cytoskeletons in the MDA231 cells ( Figure 5C ). As shown in Figure 5C , the reduction of lncRNA-ZEB2-AS1 expression depressed the phosphorylation levels of LIMK and cofilin, and the cytoskeleton was abolished. These results indicated that reduction of lncRNA-ZEB2-AS1
suppressed EGF-induced F-actin polymerization in MDA231 cells.
| Clinical relevance of lncRNA-ZEB2-AS1 between ZEB2 and EMT related markers in human breast cancer
In order to further indicate the clinically relevant by which lncRNA-ZEB2-AS1 modulated ZEB2 and EMT related markers. We detected the lncRNA-ZEB2-AS1 expression and its association with the expression levels of ZEB2 in the clinical tissues of breast cancer paired with breast cancer specimens and ANT specimens. The relationship between the expression levels of EMT related markers and lncRNA-ZEB2-AS1 was investigated. In Figure 6 , a positive correlation among lncRNA-ZEB2-AS1, ZEB2, and vimentin in 30 tested clinical specimens was observed, whereas lncRNA-ZEB2-AS1 was negatively correlated with E-cadherin. All the results suggested that lncRNA-ZEB2-AS1 in the ZEB2 and EMT-related markers is clinically relevant in breast cancer.
| D ISCUSS I ON
An increasing number of studies have reported that LncRNA considerably affects cellular processes, such invasion, metastasis, metabolism, and apoptosis. 21, 22 LncRNAs monitor carcinogenesis principally via modulating the expression levels of oncogenes or tumor suppressors. 19 Many studies revealed that LncRNA-ZEB2-AS1
decreases tumor growth and metastasis in HCC. 23 LncRNA-ZEB2-AS1 is a newly discovered lncRNA, whose clinical meaning, biological roles, and explicit mechanism are poorly understood in breast cancer. We first confirmed that lncRNA-ZEB2-AS1 is abnormally expressed in breast cancer specimens, and this abnormality is related ZEB1 and ZEB2 cardinal proteins of the ZEB family. These proteins promote EMT in cancer. Transcription factor attributing to especial Zinc finger protein families, usually located in the downstream of some signaling pathways executing EMT process in normal and pathological conditions. 24 Previous discuss have indicated that there is ectopic of ZEB in tumor and is associated with poor prognosis in patients. 25 ZEB1 is a novel protein and pivotal transcription factor in EMT progress. ZEB2 protein might have a tumor promoter role because it controls cell cycle progression and cell differentiation. 26 Wang et al found that E2F1 promoted EMT by modulating the promoter region of ZEB2 in NSCLC. 27 ZEB2 is a transcription factor that participates in adjusting different biological activities, including the inhibition of apoptosis of vascular endothelial cells via the MAPK pathway activation. 28 Meanwhile, the mechanisms by which lncRNA-ZEB2-AS1 regulates EMT in breast cancer remain unknown.
In this study, we found that knocking down lncRNA-ZEB2-AS1 re- 32 Wang et al found that migration and invasion inhibitory proteins inhibit endometrial carcinoma migration via the cytoskeleton reorganization when the number of lamellipodia are markedly reduced. 33 It is still an unknown molecular mechanism that lncRNA-ZEB2-AS1 modulates F-actin polymerization of MDA231 cells. In the current research, we detected the rearrangement of cytoskeletal protein when lncRNA-ZEB2-AS1 was abrogated in breast cancer cells. Meanwhile, the phosphorylation levels of LIMK and cofilin were decreased after lncRNA-ZEB2-AS1
was knocked down, verifying that lncRNA-ZEB2-AS1 was related to F-actin polymerization in MDA231 cells.
Collectively, our results showed that lncRNA-ZEB2-AS1/PI3K/ Akt/GSK3β/Zeb2 axis facilitates tumor progression and is a potential prevention target in breast cancer. 
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